Form 8-K Entero Therapeutics, For: Sep 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Entero Therapeutics names new interim CEO after leadership change
September 9, 2025 5:05 PM EDTEntero Therapeutics Inc. (NASDAQ: ENTO) terminated Richard Joel Paolone as interim chief executive officer and chairman of the board without cause on September 3, 2025, according to a company statement.
The company said Paolone's termination was not due to any disagreement regarding financial reporting,... More
